Meeting
2011 ASCO Annual Meeting
Outcomes in phase II trials of metastatic breast cancer: Where is the bar?
Authors
A. Kamal
Duke University Medical Center, Durham, NC
A. Kamal , T. Zhang , A. Schneider , K. Patel , E. P. Hamilton , P. K. Marcom , J. M. Peppercorn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Immunotherapy
Track
Developmental Therapeutics
Sub Track
Clinical Trial Design
Citation
J Clin Oncol 29: 2011 (suppl; abstr 2590)
Abstract #
2590
Poster Bd #
7E
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-controlled phase II trial.
First Author: Frederik Marme
Poster
2015 ASCO Annual Meeting
Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).
First Author: Ahmad Awada
Poster
2011 ASCO Annual Meeting
Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel (wPac) for HER2-negative metastatic breast cancer (MBC): Results of a Japanese phase II study (n=120).
First Author: Y. Ito
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Second-line regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) after progression on first-line atezolizumab plus bevacizumab (Atezo-Bev): Phase 2 REGONEXT trial.
First Author: Changhoon Yoo